ADCT · ADC Therapeutics SA
$1.01
-0.04 (-3.81%)
At close · Aug 14
Market Cap
$128.94M
Shares
127.67M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.01
Open$1.02
Day$1.00–1.04
52W close$0.98–4.88
Avg vol 30d1.0M
Short int5.1M · 4.0% float · 6.1d
Short vol57%
Last earningsAug 13, 2026
DataMay 2020–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 13, 2026
Est · unconfirmed
· in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−12%
below
RSI (14)
35
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−77%
trailing
YTD return
−71%
this year
Relative strength
−91%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.99% of float · ▼ -8.0% MoM · 6.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
114 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
EPS growth
+31%
Y/Y
Free cash flow
$-141.4M
Balance sheet
$258.3M
net cash
Quant / Vol
risk profile
Volatility
91%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
9.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
Annualized estimated cost savings
· from the reorganization
$10M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
35
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-3% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.99% of float · ▼ -8.0% MoM · 6.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
114 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $5
vs 200-day avg -68%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | $36M | the six months ended June 30, 2026 | — |
|
|
|||
| Adjusted net loss per basic and diluted share non-GAAP | $0.23 | the six months ended June 30, 2026 | — |
|
|
|||
| Adjusted total operating expenses non-GAAP | $80.1M | the six months ended June 30, 2026 | — |
|
|
|||
| Best overall response rate (ORR) | 89.8% | LOTIS-7 Phase 1b data reported December 2025 | — |
| Cash and cash equivalents | $261M | As of December 31, 2025 | — |
| Complete response rate | 77.6% | LOTIS-7 Phase 1b data reported December 2025 | — |
| ZYNLONTA net product revenue | $73M | Full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADCT
this stock
ADC Therapeutics SA
|
$128.94M | -71.4% | +14.9% | — | 4.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.49B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADCT | -10.6% | -25.2% | -77.1% | -3.8% | -71.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -11.0% | -29.6% | -90.9% | -7.7% | -85.2% |
Key facts
CIK
1771910
CUSIP
H0036K147
13F (30d)
113 filings
110 filers
Visit website
Investor relations